Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Berry Genomics Awaits CFDA Approval of Noninvasive Prenatal Test

publication date: Jul 22, 2014
Berry Genomics of Beijing is seeking CFDA approval for its noninvasive prenatal test, which runs on a customized Illumina NextSeq 500 sequencer. The two companies co-developed the sequencer. Berry Genomics’ Bambni™ assay, which has completed more than 200,000 samples, includes a unique PCR-free library prep technology and proprietary RUPA™ analysis software. Berry said it is in late-stage review at the CFDA. More details....

Stock Symbol: (NSDQ: ILMN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital